Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Nailike (olverembatinib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Ascentage Pharma, Innovent Biologics, Takeda

Drug class:

Bcr-abl tyrosine kinase inhibitor

Related drugs:

BCR-ABL1 T315I	Chronic Myeloid Leukemia	BCR-ABL1 T315I	Chronic Myeloid Leukemia	olverembatinib Sensitive: B - Late Trials olverembatinib Sensitive : B	olverembatinib Sensitive: B - Late Trials olverembatinib Sensitive : B
KIT wild-type + SDHB deletion	Gastrointestinal Stromal Tumor	KIT wild-type + SDHB deletion	Gastrointestinal Stromal Tumor	olverembatinib Sensitive: C3 – Early Trials olverembatinib Sensitive : C3	olverembatinib Sensitive: C3 – Early Trials olverembatinib Sensitive : C3
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	olverembatinib Sensitive: C3 – Early Trials olverembatinib Sensitive : C3	olverembatinib Sensitive: C3 – Early Trials olverembatinib Sensitive : C3
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	olverembatinib Sensitive: C3 – Early Trials olverembatinib Sensitive : C3	olverembatinib Sensitive: C3 – Early Trials olverembatinib Sensitive : C3
BCR-ABL1 mutation	Acute Lymphocytic Leukemia	BCR-ABL1 mutation	Acute Lymphocytic Leukemia	olverembatinib Sensitive: C3 – Early Trials olverembatinib Sensitive : C3	olverembatinib Sensitive: C3 – Early Trials olverembatinib Sensitive : C3
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	olverembatinib Sensitive: C3 – Early Trials olverembatinib Sensitive : C3	olverembatinib Sensitive: C3 – Early Trials olverembatinib Sensitive : C3
BCR-ABL1 T315I	B Acute Lymphoblastic Leukemia	BCR-ABL1 T315I	B Acute Lymphoblastic Leukemia	olverembatinib Sensitive: C3 – Early Trials olverembatinib Sensitive : C3	olverembatinib Sensitive: C3 – Early Trials olverembatinib Sensitive : C3
SDHB deletion	Gastrointestinal Stromal Tumor	SDHB deletion	Gastrointestinal Stromal Tumor	olverembatinib Sensitive: C3 – Early Trials olverembatinib Sensitive : C3	olverembatinib Sensitive: C3 – Early Trials olverembatinib Sensitive : C3
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	blinatumomab + olverembatinib Sensitive: C3 – Early Trials blinatumomab + olverembatinib Sensitive : C3	blinatumomab + olverembatinib Sensitive: C3 – Early Trials blinatumomab + olverembatinib Sensitive : C3
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	venetoclax + olverembatinib Sensitive: C3 – Early Trials venetoclax + olverembatinib Sensitive : C3	venetoclax + olverembatinib Sensitive: C3 – Early Trials venetoclax + olverembatinib Sensitive : C3
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	olverembatinib + APG-115 Sensitive: D – Preclinical olverembatinib + APG-115 Sensitive : D	olverembatinib + APG-115 Sensitive: D – Preclinical olverembatinib + APG-115 Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	olverembatinib + APG-2575 Sensitive: D – Preclinical olverembatinib + APG-2575 Sensitive : D	olverembatinib + APG-2575 Sensitive: D – Preclinical olverembatinib + APG-2575 Sensitive : D